Diamyd Medical
Stockholm · Founded 1994
About Diamyd Medical
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.
Company Facts
- Founded: 1994
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $68.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: sto:DMYD-B
- Website: diamyd.com
- Phone: +46 8 661 00 26
Industries & Categories
Biotechnology, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/diamyd-medical-19005 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.